Awshad, a fast-growing direct-to-consumer (D2C) wellness startup in India, has reported a profit for FY25. This puts them among the first homegrown D2C brands in the medical cannabis category to reach this point while growing sustainably. The company points to its business model, consistent revenue growth, and customer acceptance as reasons for this success.
To celebrate, Awshad is launching a stronger product: a 6500mg CBD oil. It’s meant for serious conditions like chronic pain, cancer symptoms, epilepsy, anxiety, and insomnia. It’s one of the strongest CBD products available in India.
According to Shivam Singhee, CEO & Co-Founder of Awshad, this new oil is a game-changer for the Indian wellness market. He says the company is focused on shaping the future of medical cannabis wellness through research and innovation.
In the last four years, Awshad has grown from selling CBD oils to a range of products, including capsules, mushroom supplements, gummies, and pet wellness items. They say they’ve served over 10,000 customers and have seen 20X growth since they started. Cities are driving demand, with places like Indore and Jaipur growing quickly. Their main customers are millennials and young professionals.
Awshad’s profitability comes as the medical cannabis and CBD wellness market in India gains traction. The market is expected to jump from USD $1.3 billion in FY24 to $4.7 billion in FY32, a 17.34% increase each year. This is due to increased awareness, changing regulations, and more people wanting natural treatments.
Awshad plans to grow by expanding where it sells, getting more medical professionals on board, and offering more products. The company believes that clear policies and education will shape the industry’s future and wants to play a role in this through research and expansion plans.
Awshad’s profit shows the potential for science-backed brands to create successful businesses. The company’s innovation, market approval, and plan for growth could make it one of the fastest-growing D2C wellness startups in 2025.
